The US patent no. 8,022,279 includes the key composition features of CPX-351, a liposome formulation that co-encapsulates cytarabine and daunorubicin at a synergistic 5:1 molar ratio.
Additionally, the company has also received two patents from the Japanese Patent Office.
The Japanese patent covers CombiPlex method of developing drug combinations as well as the company’s metal-based drug loading technology.
Celator CEO Scott Jackson said the positive results for CPX-351 in a previously reported Phase 2 clinical trial have supported the planning for a pivotal Phase 3 registration trial.
"With the Patent Term Adjustment, the US patent provides protection until September 2027 which, should we be successful in gaining regulatory approval, significantly extends," Jackson said.